Inferring Target Occupancy for Pembrolizumab
Pembrolizumab (Pembro), an anti-PD-1 antibody, has been approved for several cancer indications at 200 mg…
CertaraSeptember 16, 2024
Dynamic Target-Mediated Drug Disposition (TMDD)
Abstract Methods: We have developed a novel pharmacokinetic model, termed dynamic TMDD, to mechanistically describe the…
CertaraSeptember 16, 2024
Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors
Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…
CertaraSeptember 16, 2024
Blinatumomab Trimer Formation
Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…
CertaraSeptember 16, 2024
Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities
Panelists: Adekemi Taylor, PhD, VP, Quantitive Science Services at CertaraJoab Williamson, Director of Clinical Operations,…
CertaraSeptember 16, 2024
A tutorial on physiologically based pharmacokinetic approaches in lactation research
The tutorial by Amita Pansari, Xian Pan, Lisa M. Almond, and Karen Rowland-Yeo examines the…
CertaraSeptember 16, 2024
All You Need to Know About Non-CRF Data in Clinical Trials
We look at the role of non-CRF data in clinical trials, and best practices for…
CertaraSeptember 16, 2024
Why Should You Use LOINC Codes For SDTM?
September 16, 2024 In this blog, we take a detailed look at LOINC Codes and…
CertaraSeptember 16, 2024
The SDTM Mapping Process Simplified
SDTM mapping can be one of the most challenging programming problems in a clinical trial…
CertaraSeptember 16, 2024
